n e w s a n d v i e w s nature medicine volume 22 | number 12 | December 2016 1389 diastolic function and thus delays cardiac aging, they studied hypertension-induced cardiac hypertrophy and remodeling and heart-failure progression in the salt-sensitive rat strain (Dahl) fed a high-salt diet (a model for human hypertension-induced congestive heart failure), and further demonstrated the cardioprotective functions of spermidine in this model. Importantly, through pharmacological means and the use of transgenic mice, the authors were able to show that dietary supplementation of spermidine leads to an upregulation of autophagy-indicated by the presence of enhanced autophagosomes and autolysosomes (and, importantly, enhanced autophagic flux)-and a substantial increase of mitophagy in cardiomyocytes of young and old mice treated with spermidine. The cardioprotective effects of spermidine were dependent on Atg5, a critical regulator of autophagy. They also found in the Dahl rat evidence for a role of autophagy in the cardioprotective effects of spermidine in these rats.
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Resveratrol and spermidine increase autophagy through a similar mechanism 7 , in parallel with a reduction in inflammation and oxidative stress that improves cardiovascular protection 8 . Because calorie restriction and its mimetics (for example, resveratrol) confer substantial health benefits to aging animals, it could be suggested that spermidine might be another calorieassociated memory loss and motor impairment in flies. Furthermore, it has been shown that autophagy is required for the prevention of cardiomyopathy associated with age 4 . As of now, calorie restriction is the most robust nongenetic intervention known to extend lifespan in invertebrates and mammals, which it does by improving mitochondrial respiratory efficiency and delaying age-associated diseases. Different natural compounds considered to be calorie-restriction mimetics, such as resveratrol, rapamycin, acarbose and metformin, can also increase health span in mammals 5 .
Here Eisenberg et al. 1 show that dietary supplementation of spermidine given to wildtype mice leads to an extension of lifespan that is associated with a decrease in cardiac hypertrophy and a delay of age-induced diastolic dysfunction. The authors also elegantly demonstrate that spermidine confers protection of the elasticity and mechanosensitivity function of cardiomyocytes, at least in part, through structural preservation of the cytoskeleton and the myofibrils, attenuation of inflammation and preservation of mitochondrial respiration, all of which are essential for the maintenance of cardiac health during aging 6 . The authors further show that the treatment of old male and female mice with spermidine late in life is effective at extending their lifespans. To understand the mechanism by which spermidine improves Aging is a major risk factor for chronic diseases, including cardiovascular disease (CVD). In developed countries, the leading causes of death are ischemic heart disease and stroke, and their incidence increases exponentially with age. Therapeutic approaches developed in the past three decades for CVD have been focused on interventions that target particular risk factors, such as high cholesterol levels and high blood pressure, rather than targeting the underlying mechanisms for the development of CVD. As the heart ages, there is a progressive decline in cardiac structure and function that is characterized by hypertrophy, increases in collagen, decreases in diastolic filling rates and impaired left ventricular function. The underlying molecular mechanisms of cardiac aging involve altered macromolecular composition, mitochondrial dysfunction, increased oxidative stress, loss of proteostasis and declines in autophagya mechanism of cellular repair-among others. In this issue of Nature Medicine, Eisenberg et al. 1 report that they delivered the polyamine spermidine as a dietary supplement to laboratory animals and achieved striking results, including a decrease in cardiac hypertrophy and a delay in the onset of diastolic dysfunction with aging. Furthermore, life-long supplementation of mice with spermidine led to substantial increases in median lifespan, which was also observed when implementation occurred late in life (Fig. 1) .
Spermidine is a polyamine that is present in our diet and is essential for the proper function of many metabolic processes. Polyamines are involved in nearly every cellular function, including the activation of autophagy, DNA stability, transcription, translation and apoptosis, among others 2 . In their study, Eisenberg et al. 1 expand their previous observations in yeast, flies and worms, in which they showed that lifespan and health span can be extended through the induction of autophagy by spermidine 3 . Spermidine also delayed both ageSpermidine to the rescue for an aging heart
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Rafael de Cabo is at the National Institute on Aging, US National Institutes of Health, Baltimore, Maryland, USA. Pácido Navas is at Centro Andaluz de Biología del Desarrollo, CABD-CSIC, CIBERER, Instituto Carlos III, Universidad Pablo de Olavide, Sevilla, Spain. e-mail: decabora@grc.nia.nih.gov restriction mimetic 4 . Notably, using data from a prospective population-based cohort, these authors 1 also show that humans given high levels of dietary spermidine had lower protein markers of cardiac failure, a finding that is in agreement with the benefits observed in animal models. A key question for the future is whether the effects of spermidine on CVD and longevity are translatable to humans. Joining a growing list of compounds that have been shown to extend lifespan or health span in rodents (for example, metformin, resveratrol, rapamycin and acarbose), spermidine is now a leading candidate for treating the underlying mechanisms of age-related CVD in humans 9 . Unlike other compounds, there are no side effects known for spermidine. In fact, spermidine is present in many foods in our diet, including beans, fermented cheeses, meats, fruits, vegetables and mushrooms. There is evidence that the levels of spermidine in humans decrease with age, and that a diet rich in spermidine is able to increase blood and tissue spermidine levels 10 . Thus, it could be relatively easy for most people to get the benefits of spermidine through dietary modifications or by supplementation, and thus validate its potential as a new therapeutic approach for cardioprotection against aging, particularly in those with diastolic heart failure. Eisenberg et al. 1 have clearly demonstrated the beneficial effects of spermidine in cardiac protection during aging, including humans, by preserving mitochondrial function and turnover and sustained autophagy in cardiomyocytes. These properties of
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Owing to clinical success of immune-checkpoint blockade (ICB) 1 , immunotherapy is becoming a cornerstone of modern oncology, and oncoimmunology is at the forefront of cancer research. ICB unleashes naturally occurring T cells that are able to recognize cancer cells, by eliminating naturally occurring negative signals that normally hold those T cells in check to prevent autoimmune attack 2 . ICB has produced durable clinical responses and improved survival across a variety of cancers 1,2 . Two immunotherapeutic strategies are currently in the clinic. One targets cytotoxic T lymphocyte-associated protein (CTLA)-4,an intrinsic regulator of T cell activation 1, 3 . The other targets the programmed cell death 1 (PDCD1, also known as PD-1)-PD ligand 1 pathway, an extrinsic 'off ' signal that helps to control T cell activation 1,2 . The approval of these therapies for the treatment of melanoma and lung cancer 3 forever changed the landscape of cancer treatment. Yet, it must be realized that only a minority of patients treated with these drugs experience substantial clinical benefit, and thus novel and improved immunotherapy approaches are needed. In this issue of Nature Medicine, Moynihan et al. 4 showed in mouse models that a rational combination of four complementary immunomodulatory agents can lead to robust complete responses in the setting of large, immunosuppressive tumors (Fig. 1) .
Immunity results from a complex interplay between the innate immune system (which is antigen-nonspecific) and the adaptive immune system (which is antigen-specific) (reviewed in ref. 5 ). Owing to their capacity to sense and capture invading microbes and transmit the resulting information to lymphocytes, dendritic cells (DCs) link the innate and adaptive immune responses and orchestrate protective immunity, and thus activation of these would be a desirable aspect of an immunotherapeutic response 5 . T cells with activity against cancer-specific antigens can be elicited and/ or restored in two major ways: through adoptive transfer, as validated by the clinical success of genetically engineered T cell therapies 6 , or through induction in vivo by vaccination or endogenous mechanisms elicited subsequentlyto other anti-cancer therapies (for example, chemotherapy, targeted therapies or anticancer antibodies) 7 .
To realize the full potential of immunotherapy, combination approaches that tackle multiple components of tumor environments are needed to activate multiple arms of the immune system. These include neutralizing tumor-promoting inflammation, broadening T cell repertoires to multiple antigens, exploiting regulatory mechanisms that keep T cells in check and harnessing the individual variability of immune response 8 . Such efforts could pave the way for resolving natural and acquired resistance to ICB and, potentially, other anti-cancer therapies. Combination therapies targeting the CTLA-4 and PD-1 checkpoints further extend progression-free survival of patients with metastatic melanoma 9 . However, immune-related toxicity represents a crucial limiting factor 9 , and thus necessitates the development of alternative approaches. Because the T cells that are able to recognize and kill cancer cells are the effectors of ICB, their numbers and/ or functions and dysfunctions might underpin ICB resistance. That could be especially true for tumors without an obvious T cell infiltrate and/or with cancer-promoting inflammation by which T cells are redirected from cancer elimination to the secretion of cancer-promoting factors (reviewed in ref. 8 ).
In the study by Moynihan et al. 4 , the four different immune components that the authors use to generate a combinatorial immune response to tumors are: (i) an innovative anti-tumor vaccine that is composed of short peptides from well-defined tumor antigens and CpG DNA and that is carried by albuminbinding lipids, which allows it to target tumor
